Adherence to a Semiannual Surveillance Program for Hepatocellular Carcinoma in Patients with Liver Cirrhosis

Journal of Clinical Gastroenterology

Volumn 51, Issue 6, 2017, Pages 557-563

  Mancebo, Alejo ^a   González DIéguez, María Luisa ^a   Navascués, Carmen A ^a   Cadahía, Valle ^a   Varela, María ^a   Pérez, Ramón ^a   Rodrigo, Luis ^a   Rodríguez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

adherence; cirrhosis; hepatocellular carcinoma; surveillance; ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; SORAFENIB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG USE; ECHOGRAPHY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPLICATION; LIVER TUMOR; MASS SCREENING; METABOLISM; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; ULTRASONOGRAPHY;

EID: 84992406200     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000734     Document Type: Article

References (27)

1. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
2. European Association For The Study of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
3. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
4. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204-209.
5. Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular cancer in chronic liver disease: a systematic review. Ann Intern Med. 2014;161:261-269.
6. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11: e1001624.
7. Poustchi H, Farrell GC, Strasser SI, et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54:1998-2004.
8. Varela M, Reig M, De la Mata M, et al. Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers. Med Clin (Barc). 2010;134:569-576.
9. Singal AG, Yopp A, S Skinner C, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27: 861-867.
10. Singal AG, Volk ML, Rakoski MO, et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45: 727-732.
11. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-141.
12. Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432.
13. Aberra FB, Essenmacher M, Fisher N, et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160.
14. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477.
15. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
17. Edenvik P, Davidsdottir L, Oksanen A, et al. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2015;35: 1862-1871.
18. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol. 2009;15: 5907-5915.
19. Clarke TC, Soler-Vila H, Fleming LE, et al. Trends in adherence to recommended cancer screening: the US population and working cancer survivors. Front Oncol. 2012;2:190.
20. Henrion J, Libon E, De Maeght S, et al. Surveillance for hepatocellular carcinoma: compliance and results according to the aetiology of cirrhosis in a cohort of 141 patients. Acta Gastroenterol Belg. 2000;63:5-9.
21. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology. 2011;54:1987-1997.
22. Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128:90.e1-e7.
23. Jepsen P, Ott P, Andersen PK, et al. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med. 2012;156:841-847.
24. Mancebo A, González-Diéguez ML, Cadah?a V, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11:95-101.
25. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249-257.
26. Kennedy NA, Rodgers A, Altus R, et al. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J. 2013;43: 772-777.
27. Singal AG, Yopp A, SSkinner C, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen InternMed. 2012;27:861-867.